New option for the initial management of metastatic pancreatic cancer?

Journal of Clinical Oncology

Volumn 32, Issue 23, 2014, Pages 2405-2407

  Abbruzzese, James L ^a   Hess, Kenneth R ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL DEATH; CELL TRANSFORMATION; CYTOTOXICITY; DRUG EFFICACY; GENE MUTATION; GENE TARGETING; HUMAN; METASTATIC PANCREATIC CANCER; MOLECULAR GENETICS; NOTE; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADENOCARCINOMA; ANALOGS AND DERIVATIVES; FEMALE; MALE; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; PACLITAXEL; PANCREATIC NEOPLASMS;

EID: 84905822932     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.4155     Document Type: Note

References (16)

1. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
2. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
3. Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461, 2009
4. Kim MP, Evans DB, Wang H, et al: Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4:1670-1680, 2009
5. Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806, 2008
6. Ostrem JM, Peters U, Sos ML, et al: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503:548-551, 2013
7. Gysin S, Salt M, Young A, et al: Therapeutic strategies for targeting ras proteins. Genes Cancer 2:359-372, 2011
8. Luo J, Emanuele MJ, Li D, et al: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848, 2009
9. Beatty GL, Torigian DA, Chiorean EG, et al: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 19:6286-6295, 2013
10. Barrett DM, Singh N, Porter DL, et al: Chimeric antigen receptor therapy for cancer. Annu Rev Med 65:333-347, 2014
11. Thompson CB, Shepard HM, O'Connor PM, et al: Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 9:3052-3064, 2010
12. Provenzano PP, Cuevas C, Chang AE, et al: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418-429, 2012
13. Lyssiotis CA, Cantly LC: Targeting metabolic scavenging in pancreatic cancer. Clin Cancer Res 20:6-8, 2014
14. Chini CC, Gonzalez-Guerrico A, Nin V, et al: Targeting of NAD metabolism in pancreatic cancer cells: Potential novel therapy for pancreatic tumors. Clin Cancer Res 20:120-130, 2014
15. Son J, Lyssiotis CA, Ying H, et al: Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496:101-105, 2013
16. Ying H, Kimmelman AC, Lyssiotis CA, et al: Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149:656-670, 2012